Anavex Life Sciences (AVXL: NASDAQ) Investor Relations Material

Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company focused on developing drug candidates for central nervous system (CNS) diseases, announced impressive progress on its lead drug candidate, ANAVEX 2-73. The drug candidate is currently in Phase III clinical trials for the treatment of Alzheimer's disease, Phase III clinical trials to treat pediatric patients with Rett syndrome, and Phase II clinical trials for the treatment of Parkinson's disease. The drug is also being studied in preclinical trials for its potential to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. ANAVEX 2-73 is demonstrating promising results in treating Alzheimer's disease, which currently affects over 5 million people in the United States. The drug candidate has also shown potential in treating other CNS diseases, including Rett syndrome and Parkinson's disease. The company's drug candidate portfolio also includes ANAVEX 3-71, currently in Phase I clinical trials for the treatment of frontotemporal dementia, as well as preclinical drug candidates ANAVEX 1-41, ANAVEX 1066, and ANAVEX 1037. Each has potential uses for treating a variety of neurodegenerative diseases, including depression, stroke, and cancer. Founded in 2004 and headquartered in New York, Anavex Life Sciences Corp. is positioning itself as a leader in developing new treatments for CNS diseases. With impressive progress made on its lead drug candidate, ANAVEX 2-73, the company is poised for continued growth and success in the biopharmaceutical industry.